Standout Papers
Immediate Impact
64 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
2024 Standout
Works of Lori Steelman being referenced
PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
2019
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Lori Steelman | 263 | 54 | 56 | 109 | 89 | 22 | 330 | |
| Michaël H. Meel | 149 | 39 | 30 | 165 | 64 | 20 | 354 | |
| Rongjie Tao | 108 | 80 | 40 | 142 | 111 | 27 | 351 | |
| K. Carson | 115 | 46 | 19 | 139 | 66 | 15 | 341 | |
| Kathleen McCortney | 130 | 36 | 28 | 131 | 83 | 20 | 306 | |
| Frank Bouttens | 227 | 79 | 38 | 111 | 74 | 15 | 322 | |
| Zhiyong Qin | 140 | 46 | 39 | 82 | 98 | 18 | 275 | |
| Alberto Pïcca | 177 | 90 | 42 | 118 | 77 | 27 | 313 | |
| Rajiv Desai | 106 | 18 | 47 | 78 | 33 | 12 | 263 | |
| Jennifer Elster | 125 | 50 | 19 | 145 | 68 | 26 | 310 | |
| Ryan Merrell | 146 | 59 | 59 | 46 | 51 | 35 | 260 |
All Works
Loading papers...